Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RidgetechFRA:7QL 40 Debt-to-Equity is 0.16 as of Sep. 2025, which is 89% below its 10-year median of 1.49. GuruFocus rates FRA:7QL with a GF Score™ of 40/100 and a GF Value™ of €2,118,249.18. The stock has 5 warning signs investors should review. Among 557 Healthcare Providers & Services companies, Ridgetech ranks better than 72.89% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ridgetech's Debt-to-Equity or its related term are showing as below:
FRA:7QL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16 Med: 1.49 Max: 2.64
Current: 0.16
During the past 13 years, the highest Debt-to-Equity Ratio of Ridgetech was 2.64. The lowest was 0.16. And the median was 1.49.
FRA:7QL's Debt-to-Equity is ranked better than 72.89% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.4
vs FRA:7QL: 0.16
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ridgetech Debt-to-Equity Related Terms
Ridgetech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ridgetech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7QL vs DHTI, PMHS, BLMH: Debt-to-Equity Comparison
For the Pharmaceutical Retailers subindustry, Ridgetech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ridgetech Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ridgetech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ridgetech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ridgetech (FRA:7QL) has a Debt-to-Equity of 0.16 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ridgetech and its competitors. This is 89% below median its historical median of 1.49. Over the past decade, Ridgetech's Debt-to-Equity has ranged from 0.16 to 2.64. According to the industry distribution chart, Ridgetech ranks #151 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 27.1%.
Is Ridgetech's Debt-to-Equity too high?
Ridgetech's current Debt-to-Equity of 0.16 is 89% below median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 2.64. The Healthcare Providers & Services industry median Debt-to-Equity is 0.40. Ridgetech's value of 0.16 is 60% below this industry median. Based on the distribution chart, Ridgetech ranks #151 out of 557 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Ridgetech has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Ridgetech's Debt-to-Equity compare to DHTI and PMHS?
According to the Healthcare Providers & Services industry distribution chart, Ridgetech ranks #151 out of 557 companies for Debt-to-Equity. This puts Ridgetech in the upper half of its industry. The industry median Debt-to-Equity is 0.40. Ridgetech's value of 0.16 is 60% below this benchmark. Historically, Ridgetech's own Debt-to-Equity has ranged from 0.16 to 2.64 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 0.40, Ridgetech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.40, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ridgetech's current Debt-to-Equity of 0.16 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ridgetech and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ridgetech's current Debt-to-Equity is 0.16, which is 89% below median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ridgetech stock overvalued right now?
Ridgetech (FRA:7QL) has a current Debt-to-Equity of 0.16. The stock's GF Value™ is €2,118,249.18, compared to a current price of €20,304.00 — trading 99% below its estimated fair value. The current Debt-to-Equity is 0.16, which is 89% below median its 10-year median of 1.49 and 60% below the Healthcare Providers & Services industry median of 0.40. Ridgetech's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ridgetech (FRA:7QL), the current Debt-to-Equity is 0.16 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ridgetech (FRA:7QL) Overvalued in 2026?
Based on GuruFocus' analysis, Ridgetech stock appears to be undervalued.
The current stock price of €20,304.00 is trading 99% below its estimated GF Value™ of €2,118,249.18.
Key valuation signals for FRA:7QL:
Debt-to-Equity: 0.16 (89% below median its 10-year median of 1.49)
GF Value™: €2,118,249.18 vs. price of €20,304.00 (99% below fair value)
Industry Position: 60% below the Healthcare Providers & Services median (#151 of 557)
No single metric tells the full story. See the FRA:7QL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ridgetech Inc formerly China Jo-Jo Drugstores Inc is a retailer and distributor of pharmaceutical products. The company's operating segments include Retail drugstores, Online Pharmacy, and Drug wholesale. Retail drugstores segment sells prescription and over-the-counter medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy segment sells drugs through third-party platforms such as Alibaba's Tmall, JD.com, and Amazon.com. It generates maximum revenue from the Retail drugstores segment.
40GF Score
Get the complete analysis for FRA:7QL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7QL has been successfully added to your 
